Goldman Sachs Group Inc Uro Gen Pharma Ltd. Call Options Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding URGN
# of Institutions
113Shares Held
24MCall Options Held
46.9KPut Options Held
44.3K-
Rtw Investments, LP New York, NY3.26MShares$53.4 Million0.78% of portfolio
-
Great Point Partners LLC Greenwich, CT2.62MShares$43 Million9.62% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$37.7 Million0.26% of portfolio
-
Black Rock Inc. New York, NY1.72MShares$28.1 Million0.0% of portfolio
-
Cowen And Company, LLC1.63MShares$26.7 Million0.82% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $373M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...